Duisburg, Germany
Emergence Therapeutics, established in 2019, is a prominent European biopharmaceutical company based in Germany. The company specializes in creating advanced antibody-drug conjugates (ADCs) targeting high-priority cancers, particularly through the innovation of effective immuno-therapeutics for Nectin-4 and other cancers.
The clinical significance of Nectin-4 is supported by the documented success of enfortumab vedotin, a treatment approved by the US FDA for urothelial cancers, positioning Emergence Therapeutics at the forefront of biotechnology innovation. The company's ongoing exploration of additional ADCs aims to address unmet therapeutic needs.
Backed by a substantial €87.00M Series A investment in December 2021, the company attracts diverse investors such as Bpifrance, Kurma Partners, Pontifax, RA Capital Management, and others. These investments highlight investor confidence in Emergence Therapeutics' potential to make significant strides in the healthcare industry.
